Dr Andrew Lightfoot (CEO) joined Procarta as CEO in 2017. Andrew is a medicinal chemist by background and has 19 years’ experience in leading drug discovery/development in multiple therapeutic areas (antimicrobials, neurosciences and immuno-inflammation) in both large pharma and biotech. From 2011-17, he was founder, CEO and Director of Peptinnovate, a respiratory drug discovery and development company, which he took from early discovery to Phase 1 clinical studies.
At GSK, 1998-2010, he led discovery efforts leading to a number of molecules progressing into clinical trials. He was part of the out-licensing team of a number of assets to Proximagen in 2011. From 2010-11 he was Chief Executive Officer of Helperby Therapeutics where he helped design and execute a phase 2a clinical study for MRSA. From 2012-14, he was an NED of CytaCoat AB, a Swedish antimicrobial coating company. He is a Board member of the BioIndustry Association (BIA).
Dr Martin Stocks (COO) has over 30 years’ experience in research and scientific commercialisation, including in the area of nucleic acid-based biopharmaceuticals. Founder and CSO of one biotech company (Iclectus Ltd.), he has also managed a specialist CRO (The Model Gut).
He manages the "Health and Medical" portfolio of Plant Bioscience Ltd., a private technology transfer company and is an Investment Executive of the Iceni Seedcorn Fund. Martin has raised close to £12m in VC and translational funding for early-stage ventures/projects, and has negotiated and secured over 50 service or licensing deals including with major pharma (Merck & Co., Novartis, GSK, Pfizer), animal health (Elanco, Ceva), and agbio (Monsanto, Syngenta) companies as well as mid-tier entities and SMEs.
Prof. Michael McArthur (CSO, Co-Founder) is the Professor of Nanomedicine at the Norwich School of Medicine, UEA. He is a Molecular Microbiologist with over 20 years experience of academic and biotechnology research. His defining scientific interest is how the control of bacterial genes can be used to create new antibacterials. He leads multidisciplinary research teams with expertise in: molecular biology, microbiology, chemistry, biophysical characterisation and formulation.
Michael gained his PhD from University of Cambridge and has held academic positions in the EU (John Innes Centre, ICMB in Crete) and University of Washington, Seattle. Whilst there his technologies were used to found a diagnostics company, Regulome Inc, for whom he served as Director of Research. He is named on 15 patents and help raise $30m in private and grant funding.
Dr Nikki D’Arcy (Operations Director) has recently been recruited to Procarta team. She is an experienced project manager with over 15 years’ experience in molecular and microbiology gained in world-leading Universities and research institutes, hospitals, and industry.
She has extensive cell biology, microbiology and molecular biology technical expertise as well as excellent operational and laboratory managerial skills gained in a range of roles. She has published in numerous international peer-reviewed journals and holds a PhD in Molecular Microbiology from UCL and holds a PRINCE2 project management qualification.